(R)-2-乙氧基-3-(4-羟基苯基)-丙酸 | 325793-69-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: (R)-2-乙氧基-3-(4-羟基苯基)-丙酸
• 英文名称: (R)-2-ethoxy-3-(4-hydroxyphenyl)propanoic acid
• 英文别名: (R)-2-Ethoxy-3-(4-hydroxy-phenyl)-propionic acid；(2R)-2-ethoxy-3-(4-hydroxyphenyl)propanoic acid
• CAS: 325793-69-9
• 化学式: C₁₁H₁₄O₄
• 分子量: 210.23
• InChiKey: FMJUDUJLTNVWCH-SNVBAGLBSA-N

物化性质

• 沸点：
  390.8±27.0 °C(Predicted)
• 密度：
  1.225±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

反应信息

• 作为产物：
  描述：

  2-乙氧基-3-对羟基苯基丙酸乙酯 在 α-chymotrypsins from bovine pancreas 作用下， 以 aq. buffer 为溶剂， 以71.429%的产率得到
  参考文献：
  名称：

  Process Development on the Enantioselective Enzymatic Hydrolysis of S-Ethyl 2-Ethoxy-3-(4-hydroxyphenyl)propanoate

  摘要：

  A novel biocatalytic approach for the large-scale production of S-2-ethoxy-3-(4-hydroxyphenyl)propanoic acid S-1 from its racemic ethylester rac-2 by enantioselective hydrolysis has been developed. S-1 is an important building block in the synthesis of PPARalpha and -gamma agonists such as Ragaglitazar [NNC 61-0029 ((-)DRF2725)]. The development history comprises enzyme screening, biocatalyst and process optimization, and scale-up to pilot plant. The project was thereby highly interdisciplinary by combining biotechnology and chemistry technologies. The final process was successfully run on a 44-kg pilot scale in 43-48% yields and with high enantiomeric purities (98.4-99.6% ee).

  DOI：

  10.1021/op0256035

文献信息

• Process for the preparation of substituted 3-phenyl-propanoic acid esters and substituted 3-phenyl-propanoic acids
  申请人：——

  公开号：US20030008361A1

  公开（公告）日：2003-01-09

  The present invention relates to a process comprising hydrolysis or trans esterification of one of the two enantiomeric forms of a racemic or enantiomerically enriched ester of formula I or IV by a higher rate than the other by an enzyme to give an ester and a acid (III) or two different esters (V) and (VI) with different R groups both with increased enantiomeric purity and a esterification process of a racemic or enantiomerically enriched acid (VII) by an enzyme to give an ester and an acid both with increased enantiomeric purity.

  本发明涉及一种过程，包括通过酶催化作用使公克混合物或对映富集的酯化合物I或IV的两种对映异构体中的一种水解或酯交换速率高于另一种，从而得到具有提高对映纯度的酯和酸III或具有不同R基团的两种不同酯V和VI，以及通过酶催化作用酯化公克混合物或对映富集的酸VII，从而得到具有提高对映纯度的酯和酸。
• Stereoselective estarase from aspergillus oryzae
  申请人：——

  公开号：US20030199048A1

  公开（公告）日：2003-10-23

  An esterase isolated from Aspergillus oryzae is capable of stereoselective hydrolysis of chiral esters and also has arylesterase activity (EC 3.1.1.2) and feruloyl esterase activity (EC 3.1.1.73). The esterase has only a limited homology to known amino acid sequences.

  从米曲霉中分离出的酯酶能够立体选择性地水解手性酯，并具有芳基酯酶活性（EC 3.1.1.2）和feruloyl酯酶活性（EC 3.1.1.73）。该酯酶与已知氨基酸序列仅具有有限的同源性。
• PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES
  申请人：METABOLIC SOLUTIONS DEVELOPMENT CO., LLC

  公开号：US20160152570A1

  公开（公告）日：2016-06-02

  The present invention relates to hydroxamate compounds and pharmaceutical compositions that are useful for treating and/or preventing metabolic inflammation mediated diseases such as diabetes, obesity, hypertension, dyslipidemia, a neurodegenerative disorder (e.g., Alzheimer's disease, Parkinson's disease, or Huntington's disease), or any combination thereof. Moreover, the present invention also provides methods of treatment for these diseases or disorders.

  本发明涉及羟酰胺化合物和药物组合物，其对于治疗和/或预防代谢性炎症介导的疾病如糖尿病、肥胖症、高血压、血脂异常、神经退行性疾病（例如阿尔茨海默病、帕金森病或亨廷顿病）或任何这些疾病的组合具有用处。此外，本发明还提供了治疗这些疾病或疾病的方法。
• PROCESS FOR THE PREPARATION OF SUBSTITUTED 3-PHENYL-PROPANOIC ACID ESTERS AND SUBSTITUTED 3-PHENYL-PROPANOIC ACIDS
  申请人：NOVO NORDISK A/S

  公开号：EP1206565A1

  公开（公告）日：2002-05-22
• STEREOSELECTIVE ESTERASE FROM ASPERGILLUS ORYZAE
  申请人：Novozymes A/S

  公开号：EP1309674B1

  公开（公告）日：2007-06-13